Table 3.
Prostate‐specific antigen, kallikrein panel, MRI and biopsy pathology results among men with cancer detected in the ProScreen pilot study.
| Gleason score | PSA categorized*, ng/mL | Kallikrein panel* , † , % | PI‐RADS score | Number of cores positive | Max cancer length per core, mm | Percent Gleason pattern 4 or 5 |
|---|---|---|---|---|---|---|
| 3 + 3 | 5–10 | 40–60 | 3 | 1 | 3 | 0 |
| 3 + 3 | 3–5 | 20–40 | 4 | 1 | 9 | 0 |
| 3 + 4 | 5–10 | 20–40 | 4 | 1 | 6 | 30 |
| 4 + 3 | 10–15 | >60 | 4 | 3 | 10/4/4 | 90/80/60 |
| 4 + 3 | 3–5 | 20–40 | 5 | 1 | 8 | 80 |
| 4 + 4 | 5–10 | >60 | 5 | 1 | 5 | 48 |
| 4 + 4 | 10–15 | 20–40 | 5 | 3 | 5/1/6 | 80/100/60 |
PI‐RADS, Prostate Imaging Reporting and Data System.
*
PSA results are categorized (scale: 3–5, 5–10, 10–15 ng/mL) for privacy protection.
†
Result of the kallikrein panel expressed as probability of clinically significant prostate cancer (%), calculated from the proprietary formula of the 4Kscore and categorized (scale: <20%, 20–40%, 40–60%, >60%) for privacy protection.